Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

Dupixent is available as a solution inside single-dose prefilled pens and syringes, given as a subcutaneous injection. Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4 ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application ... the successful launch of Dupixent for chronic obstructive ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label ... of care in the anti-VEGF category. Dupixent's ongoing growth is supported by recent ...